About Stemline Therapeutics
Stemline Therapeutics is a company based in New York (United States) founded in 2003 by Ivan Bergstein was acquired by Menarini in May 2020. It operates as a Direct-to-Consumer (D2C). Stemline Therapeutics has raised $15.09 million across 4 funding rounds from investors including Pequot Capital Management and Menarini Group. The company has 131 employees. Stemline Therapeutics has completed 1 acquisition, including Primrose Therapeutics. Stemline Therapeutics offers products and services including ELZONRIS and ORSERDU. Stemline Therapeutics operates in a competitive market with competitors including Adicet Bio, ImmunoACT, Orca Bio, Ossium Health and Nordic Nanovector, among others.
- Headquarter New York, United States
- Employees 131
- Founders Ivan Bergstein
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website stemline.com
- Social LinkedIn
- Acquired by Menarini (May 2020)
- Legal Name Stemline Therapeutics, Inc.
- Annual Revenue$898.2 K (USD)0as on Dec 31, 2017
- Net Profit-$76.82 M (USD)10as on Dec 31, 2019
- EBITDA-$79.25 M (USD)8as on Dec 31, 2019
- Total Equity Funding$15.09M (USD)
in 4 rounds
- Latest Funding Round$740K (USD), Series A
Jan 2012
- InvestorsPequot Capital Management
& 1 more
- Employee Count131
- Investments & Acquisitions
- Acquired byMenarini
(May 2020)
Products & Services of Stemline Therapeutics
Stemline Therapeutics offers a comprehensive portfolio of products and services, including ELZONRIS and ORSERDU.
Used for treating blastic plasmacytoid dendritic cell neoplasm.
Indicated for ER-positive, HER2-negative advanced breast cancer.
Funding Insights of Stemline Therapeutics
Stemline Therapeutics has successfully raised a total of $15.09M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $740 thousand completed in January 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $15.09M
- Total Rounds 4
- Last Round Series A — $740,000
- First Round $12.5M
(Apr 2008)
- Investors Count 1
All 4 funding rounds of Stemline Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2012 | $740,000 | Series A | – | – | – |
| Apr 2010 | $600,000 | Series A | – | – | – |
| Mar 2010 | $1.25M | Series A | – | – | – |
| Apr 2008 | $12.5M | Series A | – | – |
2 investors in total: 2 institutional.
Investors in Stemline Therapeutics
Stemline Therapeutics has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Pequot Capital Management and Menarini Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
- | – | pequotcap.com | - | |
Menarini Group is engaged in pharmaceutical and healthcare solutions. | – | menarini.com | Florence, Italy |
Investor details for Stemline Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Stemline Therapeutics
192 people are tracked at Stemline Therapeutics (106 in leadership, 4 in board & advisors, 82 in team); the tracked headcount is 131.
| Name | Role | Group |
|---|---|---|
Ivan Bergstein | Founder & CEO | Leadership |
Ken Hoberman | Chief Operating Officer | Leadership |
Danielle Schubert | Associate Director, Marketing | Leadership |
Austin Allan | Vp, Global Head R&d Quality | Leadership |
Andrew Dorman | Senior Director, Clinical Program Lead (hematology & Kat6) | Leadership |
Corey Pelletier | Executive Director, Head of U.S. HEOR | Leadership |
Jill Dailey | VP And Chief Compliance Officer, Oncology | Leadership |
Matthew Spencer | Director, Regional Marketing, West - Elacestrant | Leadership |
Bill Ablaschai | Director, Patient Marketing, Elacestrant | Leadership |
Maria Luisa Grossi | Executive Director, Head of Commercial Strategy | Leadership |
Emmanuel Reyes-Cortes | Senior Medical Director | Leadership |
Selena Lewis Msn Rn Ocn | Regional Marketing- Associate Director | Leadership |
Kris Prasse | Regional Director | Leadership |
Susan Bergen | Director, Oncology Marketing, Regional Marketing Team | Leadership |
Molly Hollman | Director, Regional Marketing | Leadership |
Lydia N. | Director, Field Medical Operations | Leadership |
Chelsea Williams | Director, Clinical Operations | Leadership |
Shan Li O'Connor PharmD, BCOP | Regional MSL Director - Hematology | Leadership |
Yegor Voronin | Senior Director, Global Collaborative Studies, Hematology | Leadership |
Cathy Jarrold | Head of Market Access, UK Ireland and Nordics | Leadership |
172 more people are available in the full profile.
Complete people profiles for Stemline Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Stemline Therapeutics
Stemline Therapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Primrose Therapeutics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Biotechnology company focused on the development of treatments for Polycystic Kidney Disease (PKD) | primrosetherapeutics.com | New York, United States | 2010 | Sep 2011 | •••• |
Complete acquisition details for Stemline Therapeutics
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Stemline Therapeutics
6 dated milestones of Stemline Therapeutics across 17 years, from founding to its latest funding, stage changes and deals.
- Founded Stemline Therapeutics is founded.
- Funding First funding round of $12.5M.
- Acquisition Acquires Primrose Therapeutics.
- Funding Latest funding round, Series A, of $740K.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Menarini.
Competitors of Stemline Therapeutics
Stemline Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Adicet Bio, ImmunoACT, Orca Bio, Ossium Health and Nordic Nanovector, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| adicetbio.com | 2014 | Menlo Park, United States | $51M | 86 | Immune cell therapies for cancer treatment are developed. | |
| immunoact.com | 2018 | Mumbai, India | $15.87M | 195 | Cell therapies for cancer treatment are developed. | |
| orcabio.com | 2016 | Menlo Park, United States | $192M | 66 | Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders | |
| ossiumhealth.com | 2016 | San Francisco, United States | $125.41M | – | Ossium Health is focused on bioengineering for improved health. | |
| nordicnanovector.com | 2009 | Oslo, Norway | $51.69M | 40 | Antibody radionuclide conjugates are developed for haematological cancers. | |
| kiadis.com | 1997 | Amsterdam, Netherlands | $32.95M | – | Therapeutic solutions for hematopoietic stem cell transplants are developed. | |
| aurontx.com | 2018 | Wellesley, United States | $103.84M | – | Developer of cancer therapeutics for the treatment of blood cancer | |
| syros.com | 2012 | Watertown, United States | $124.4M | 117 | Small molecule therapeutics for cancer and genetic diseases are developed. |
Detailed competitors of Stemline Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Stemline Therapeutics
The website of Stemline Therapeutics (stemline.com) receives about 5.6K visits a month and ranks #3,251,325 among all websites worldwide, #4,268 in Biotechnology and Pharmaceuticals.
- Monthly visits5.6K
▼ 11.5% vs previous month
- Unique visitors2.8K
per month
- Global rank#3,251,325
among all websites
- Category rank#4,268
Health · Biotechnology and Pharmaceuticals
- Bounce rate41%
- Pages per visit1.6
- Average visit6 sec
- DevicesDesktop 40% · Mobile 60%
Websites whose visitors overlap most with Stemline Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| sunesis.com | 100% | – | – | View details | |
| vitals.com | 80% | 1.3M | #66,349 | View details | |
faculty.mdanderson.org | faculty.mdanderson.org | 60% | – | – | – |
Latest news on Stemline Therapeutics
Complete news archive for Stemline Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Stemline Therapeutics
10 companies that operate in the same segment as Stemline Therapeutics (Oncology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | 2002 | Saint-genis-pouilly, Ain, France | USD 56.13 M | USD 235.08 M | – | |
Developer of small molecule drugs for the treatment of cancer and inflammatory disease | 2008 | Natick, Massachusetts, United States | USD 98.4 M | USD 146.07 M | 279 | |
Small molecule therapeutics are developed for cancer and rare diseases. | 2017 | New York, New York, United States | USD 229.6 M | – | – | |
Small-molecule drugs for cancer treatment are developed via Degronimid platform. | 2016 | Cambridge, Massachusetts, United States | USD 223 M | USD 35.95 M | 110 | |
Developer of drugs based on T-Cell receptor technology for the treatment of cancer | 2008 | Abingdon, Oxfordshire, United Kingdom | USD 601.28 M | USD 400.95 M | 493 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Stemline Therapeutics
Stemline Therapeutics was founded in 2003 and raised its 1st funding round 5 years after it was founded.
Stemline Therapeutics is headquartered in New York, United States. It is registered at New York, New York, United States.
Ivan Bergstein is the current CEO of Stemline Therapeutics. They have also founded this company.
Stemline Therapeutics is a funded company, having raised a total of $15.09M across 4 funding rounds to date. The company's 1st funding round was a Series A of $12.5M, raised on Apr 2008.
Stemline Therapeutics has 131 employees.
Annual revenue of Stemline Therapeutics is $898.2K as on Dec 31, 2017.
Stemline Therapeutics, part of the Menarini Group, is dedicated to the development of innovative therapies in oncology. The company focuses on transforming the lives of cancer patients through a broad pipeline of transformative treatments. Their key products include ELZONRIS for blastic plasmacytoid dendritic cell neoplasm and ORSERDU for advanced breast cancer. Operations are centered in therapeutic areas with high unmet needs, contributing to advancements in cancer care.
Stemline Therapeutics's top competitors include Orca Bio, Ossium Health and Adicet Bio.
Stemline Therapeutics offers ELZONRIS and ORSERDU.
Stemline Therapeutics has made 1 acquisition, including Primrose Therapeutics.
Stemline Therapeutics has 2 investors. Key investors include Pequot Capital Management, and Menarini Group.
Stemline Therapeutics operates through Stemline Therapeutics, Inc..